Targeting the PI3K signaling pathway in cancer - Wikidata - awgldk - TriplyDB

Targeting the PI3K signaling pathway in cancer

Targeting the PI3K signaling pathway in cancer

http://www.wikidata.org/entity/Q24647554

about

Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation Phospho-tyrosine dependent protein-protein interaction network Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Clinical significance of T cell metabolic reprogramming in cancer Lin28 and let-7 in cell metabolism and cancer PI3K and AKT: Unfaithful Partners in Cancer Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells p38 MAPK and PI3K/AKT Signalling Cascades inParkinson's Disease New and emerging factors in tumorigenesis: an overview What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming Deconvoluting the obesity and breast cancer link: secretome, soil and seed interactions Phosphoinositides: tiny lipids with giant impact on cell regulation Cancer cell metabolism: implications for therapeutic targets Signaling cross-talk in the resistance to HER family receptor targeted therapy Involvement of free radicals in breast cancer A Small Molecule Inhibitor of PDK1/PLCγ1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion A Synthetic Polyphosphoinositide Headgroup Surrogate in Complex with SHIP2 Provides a Rationale for Drug Discovery Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects PITPNC1 Recruits RAB1B to the Golgi Network to Drive Malignant Secretion Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations Suppression of survival signalling pathways by the phosphatase PHLPP EGFR-TKI resistance in NSCLC patients: mechanisms and strategies Sustained proliferation in cancer: Mechanisms and novel therapeutic targets PKCη/Rdx-driven phosphorylation of PDK1: a novel mechanism promoting cancer cell survival and permissiveness for parvovirus-induced lysis Novel Role for p110β PI 3-Kinase in Male Fertility through Regulation of Androgen Receptor Activity in Sertoli Cells Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340)SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway SHIP2 multiple functions: a balance between a negative control of PtdIns(3,4,5)P₃ level, a positive control of PtdIns(3,4)P₂ production, and intrinsic docking properties.Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells.Leptin revisited: its mechanism of action and potential for treating diabetes.Cross-species proteomics reveals specific modulation of signaling in cancer and stromal cells by phosphoinositide 3-kinase (PI3K) inhibitors DNA methylation is globally disrupted and associated with expression changes in chronic obstructive pulmonary disease small airways Identification of inhibitors of inositol 5-phosphatases through multiple screening strategies.

P2860

Q24292953-6D3959BF-8048-49FD-8F26-D7102A9E1918 Q24305925-FD065021-B4BD-44A8-A37B-2B8B2FD4C004 Q24324740-48D2EC98-62FF-451E-974D-8A71EB56DA69 Q26741814-2F1FEA39-3975-41E9-814B-8F14371E5AF2 Q26741974-4B1A0BA1-063E-4F0D-993F-E43CC2578A95 Q26770347-CAE6B521-8BD9-4027-97F8-2BFB3CF5124D Q26781367-282C1462-3A45-4426-853E-4C8DE65AA20F Q26781643-BFBEEBFC-36E6-44A6-9B69-9919AA16DDAC Q26798203-15AD0514-35EC-4C37-B370-7B36BAE5746B Q26799375-F4B740D0-2D9A-4053-92A1-0A05C19D7B7C Q26801253-C2196FF4-D5DD-4D25-B542-BF558166FE28 Q26825780-5AE53003-D8F1-42B4-9281-B409A403E50B Q26864117-C54B5CBD-6EDE-4E7D-811F-9FF2772128B5 Q26991931-9EF1350A-CDD0-4757-B867-5440AF42E7E9 Q27012820-C6E9FAC7-3A1C-4DC8-B429-B04F239B4B03 Q27012953-58D99D44-3E44-462B-A24A-4281F8D1876B Q27013632-2D7D63ED-EC55-4DF7-9A7E-C63B8C673D0E Q27027778-97850C00-4F1A-404F-8FE0-67960D880ACE Q27027944-E65174C7-031F-4E51-A532-42616B15AD51 Q27314644-C8CA4420-F790-40BD-A077-EE2AA70524E0 Q27677243-D10C40FB-5FFC-4B88-9AB0-9A5AB397813C Q27711042-83F71EE1-8BA4-4564-9126-5A31D05EDA9B Q28076454-45059499-6CC4-4494-A1B4-313F2F602635 Q28118950-ADFD379C-E2FD-4312-A8E9-B9C521B752DD Q28286551-D99052AA-11CD-4C7E-A99F-DFA9A0D58221 Q28388451-55BB3843-5A93-43E4-8326-8D0111B01CF2 Q28394310-26991A0F-35FF-4A5A-9BDC-445C09ACDB46 Q28396388-89EC193C-2CEB-43C4-9C60-BC8CE6D5FDE7 Q28543893-DC86B8F0-231E-45F7-BFB9-3C3E63952B32 Q28546072-918AAACD-02B1-4D6E-96D3-4C6EACD37240 Q28547020-5E0803E9-BBC5-49A4-A7B4-59C27315FE1F Q30009047-FB6E0AF8-24F9-4663-A2BA-F4F96602A7BA Q30155578-802CB664-36D4-45E6-9CC2-7C3DA1308F9A Q30491599-85A8CF7E-1E1C-4F7F-83E7-188114C73889 Q33426189-AD6FD32B-9AD2-4053-B369-3F71CE27361B Q33554429-2E521167-7EC3-4BF4-8118-F652E39BC417 Q33602487-C7C5124B-016B-450E-8610-D1F7537869C9 Q33718705-DC693A42-C7EF-4EAA-A54E-66579A75225C Q33799715-1FDFDEC9-33C2-4268-9917-8F03A9A0EE1E Q33824783-0307B1D2-0CD8-4272-B40F-F960FC8C12E8

P2860

Targeting the PI3K signaling pathway in cancer

http://www.wikidata.org/entity/Q24647554

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Targeting the PI3K signaling pathway in cancer

@ast

Targeting the PI3K signaling pathway in cancer

@en

Targeting the PI3K signaling pathway in cancer

@nl

type

label

Targeting the PI3K signaling pathway in cancer

@ast

Targeting the PI3K signaling pathway in cancer

@en

Targeting the PI3K signaling pathway in cancer

@nl

prefLabel

Targeting the PI3K signaling pathway in cancer

@ast

Targeting the PI3K signaling pathway in cancer

@en

Targeting the PI3K signaling pathway in cancer

@nl

P1433

Q24647554-5404055E-B290-4F36-A71F-BD3D334CF9E7

P1476

Q24647554-28E8E5EB-6DE6-4ABF-BBC6-DDEA3FE05180

P2093

Q24647554-1C0E977A-1FB5-4963-A0E6-0E866CAA999B

P2860

Q24647554-12F964F5-D451-479F-B018-425C47B00773

Q24647554-13E297C4-38C3-49D4-BAA3-E44957B939E8

Q24647554-186E52BE-6D9A-4683-B7D7-AA268D03D91F

Q24647554-23A39DF8-B403-4658-8D46-20A5B1B085E9

Q24647554-26DC8AE3-FAD9-47B7-89F0-80ECC97D75C4

Q24647554-2DFC8F07-4BFF-45FF-84C2-A23C838BDECC

Q24647554-3053F45F-E675-4178-955A-7AE884A02E41

Q24647554-428B6AAF-EA10-4B20-94A3-30F17BC1B3EA

Q24647554-4C84D32E-9232-4FA5-B938-C140F46F9F3F

Q24647554-731BA566-B744-40CE-BE3B-E61B43557B29

P304

Q24647554-94FC0608-2FED-4E11-B984-BD53C5899992

P31

Q24647554-5116FF1A-0A96-4104-8D84-B786F500DAAA

P3181

Q24647554-8F48BFE5-D9BD-43FA-BA51-2F95FB745DB6

P356

Q24647554-6ED84675-F2D9-45B0-AA56-B132C8BBF9B1

P407

Q24647554-2D0F0BFB-4037-4684-9E09-754414C60D30

P433

Q24647554-766331F7-50D6-43DF-B52C-682C2A099039

P478

Q24647554-6371B536-A056-4B4A-A72B-B13F6570C493

P50

Q24647554-0A5DAE8E-9A72-4FD4-B4C0-C15EE6354353

Q24647554-8ED28C8D-8DC6-47C9-9FE2-400FD5848F6A

P577

Q24647554-7F1C3725-B4A4-408C-939E-0584B4BF8D5F

P5875

Q24647554-BACED739-F12C-4B7F-AE12-E45D4E6AC61F

P698

Q24647554-E9AF629B-D88E-43A1-A675-836A3D299332

P932

Q24647554-A5A14921-AA6B-4CE6-B50B-20A8D0A6A6FA

P3181

P356

J.GDE.2009.11.002

P1433

Current Opinion in Genetics & Development

P1476

Targeting the PI3K signaling pathway in cancer

@en

P2093

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

P304

87-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1476657

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.GDE.2009.11.002

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Lewis C. Cantley

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40684264

http://www.w3.org/2001/XMLSchema#string

P698

20006486

http://www.w3.org/2001/XMLSchema#string

P932

2822054

http://www.w3.org/2001/XMLSchema#string